Corporate Social Responsibility | Business Wire | PR NewsWire | Marketwire | Realwire | ACN/JCN newswire | 247pressrelease | PRWeb

HemoShear, LLC, Launches HepaShear Division

CHARLOTTESVILLE, Va. - 
      HemoShear, LLC, a developer of innovative, cell-based, human surrogate 
      models for discovery and assessment of new drug compounds in the 
      laboratory announces the formation of a new division, HepaShear, to 
      develop an advanced human surrogate model of the liver.
Posted : Mon, 09 Nov 2009 20:17:38 GMT
Author : HemoShear, LLC
Category : Press Release
News Alerts by Email ( click here )
Press Release News | Home
CHARLOTTESVILLE, Va. - (Business Wire) HemoShear, LLC, a developer of innovative, cell-based, human surrogate models for discovery and assessment of new drug compounds in the laboratory announces the formation of a new division, HepaShear, to develop an advanced human surrogate model of the liver.

“HepaShear will provide scientific expertise and a proprietary model to study liver diseases and accelerate discovery of innovative drug therapies in a novel system that closely mimics the biology and architecture of the human liver,” said Brett Blackman, Ph.D., Chief Scientific Officer of HemoShear.

Utilizing HemoShear’s proprietary technology, which applies human blood flow patterns to recreate the biology of organ tissue, HepaShear will vastly improve pharmaceutical scientists’ ability to identify new drug targets and discover compounds that have a greater likelihood of successful treatment of liver diseases in humans.

“Current methods do not adequately predict human biological responses to new drugs despite extensive testing in the laboratory and in animals. The HepaShear human surrogate model of the liver will be far more predictive of human responses and reduce risk of costly drug development failures,” said Brian Wamhoff, Ph.D., Vice President of R&D for HemoShear.

Wamhoff predicted the research would have profound effects. “I fully expect we will transform the way biomedical and pharmacological research will be conducted in the future by creating vastly improved models of liver function in order to study and treat liver diseases, such as hepatitis and cirrhosis, and improve drug efficacy for metabolic disorders such as diabetes and hypercholesterolemia, ” Wamhoff said.

The Company expects to complete development of the liver model and begin HepaShear’s commercial operations by late 2010.

About HemoShear, LLC

HemoShear’s proprietary technology recreates physiological function of human cells and tissue by applying human-derived blood flow forces to cultures of primary human vascular cells in the laboratory. HemoShear works in strategic partnerships with pharmaceutical companies to identify and validate pathways of disease progression, and to assess the efficacy and safety of new drug compounds. For information about HemoShear, please visit www.hemoshear.com.

HemoShear, LLC
Jim Powers, CEO (434) 872 0198


Copyright © 2008 Business Wire. All rights reserved.
Share/Save/Bookmark



Related News

Praxis EMR Wins Top Rankings in 2009 AAFP EHR User Satisfaction Survey
CANOGA PARK, Calif., Nov. 25 /PRNewswire/ -- Praxis Electronic Medical Records received first place rankings in the American Academy of Family Physicians' (AAFP) Family Practice Management (FPM) 2009 EHR User Satisfaction Survey for improving medical quality, health ...

Magna Entertainment Corp. files fifteenth default status report
AURORA, ON, Nov. 25 /PRNewswire/ - Magna Entertainment Corp. ("MEC" or the "Company") filed this news release as its fifteenth bi-weekly default status report under National Policy 12-203 of the Canadian Securities Administrators, pursuant...

Air China Awarded at CITM in Kunming
BEIJING, Nov. 25 /PRNewswire-Asia/ -- Air China has won awards for "Best Organization" and "Best Booth" at the China International Travel Market (CITM), held in Kunming, China, between the 19th...

Air China Transports 10,000 Pilgrims to Mecca
BEIJING, Nov. 25 /PRNewswire-Asia/ -- Between 30th October to 18th November, Air China transported nearly 10,000 pilgrims to the holy meeting site of Mecca, Saudi Arabia. There are nearly 20 million Muslims in China

Being Frugal on Black Friday: Making Wise Spending Decisions for the Holidays
A new online campaign--"Festive & Frugal"--is encouraging people to think twice about purchases and celebrate the holidays without overspending. The campaign, sponsored by Orange County's The Frugality Game, is using social media tools like Facebook to spread the word that gifts...

Cap-and-Trade Bill Targets Coal Industry, Exports Jobs, Massey Energy's Don Blankenship Says in Interview With The Hill, a Prominent Washington Newspaper
JULIAN, W.Va., Nov. 25 /PRNewswire/ -- In an extensive interview with The Hill newspaper last week on

Research and Markets: Regional Supply-Demand and Circulation of Corn in China - Corn is the Second Largest Grain Crop in China
DUBLIN - Research and Markets (http://www.researchandmarkets.com/research/6620b0/regional_supplyde) has announced the addition of the

Have your Say
Name
Email
Subject
Your Comment

Enter Verification code
 
  

 
Follow The Earth Times
Subscribe to RSS Follow Earth Times on TwitterNews by email
Share/Save/Bookmark
 
 



 
Subscribe to free Earthtimes
News Alerts by Email Click here
For RSS Feeds Click here
or Create your own RSS

Add to Google Toolbar
Breaking News
Press Releases

 


The Earth Times
News Category

© 2009 www.earthtimes.org, The Earth Times, All Rights Reserved | Privacy Policy
Earth Times accept no responsibility or liability either directly or indirectly for views or opinions expressed in articles or comments.